- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01287858
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
October 29, 2015 updated by: Daiichi Sankyo, Inc.
A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects
AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily.
It is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.
Study Overview
Detailed Description
A dose-finding study of AC430 in healthy volunteers.
Study Type
Interventional
Enrollment (Actual)
88
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53718
- Covance Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Important Inclusion Criteria:
- Healthy normal males and females, age 18 to 45, inclusive, at the time of consent
- Able to communicate effectively in the English language
- Able to provide valid, written informed consent
- Able to swallow up to 20 capsules of study drug
- BMI (body mass index) ranging between 18 and 30 kg/m2, inclusive
- Minimum weight of 50 kg
- Serum Creatinine ≤ ULN (upper limit of normal) and estimated creatinine clearance at screening of ≥ 80 mL/min per the Cockcroft-Gault equation
- Total serum bilirubin ≤ ULN (may be repeated to confirm eligibility)
- Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ ULN (may be repeated to confirm eligibility)
- Male subjects must either be sterile or agree to use from Check-in until 90 days following the last dose of AC430, an acceptable form of birth control.
- Female participants must be either of non-child-bearing potential or agree to use an acceptable form of birth control.
Important Exclusion Criteria:
- History of clinically significant drug allergy
- Participation in another clinical trial with receipt of an Investigational Product within 90 days before dose administration (or 5 half-lives, whichever is longer)
- Major surgery within 90 days before study enrollment
- Use of prescription, over the counter, or herbal medications or supplements, including oral contraceptives within 14 days of check-in
- A history of drug abuse or a history of alcohol abuse within 1 year prior to Screening
- Current or recent (within 30 days before enrollment) use of tobacco or nicotine products
- Consumption of alcohol containing beverages > an average of 14 drinks per week or unwillingness to refrain from ethanol consumption while confined to the study unit
- Inadequate venous access that would interfere with obtaining blood samples
- Recipients of blood transfusion or transfusion of blood or plasma products, within 90 days before study drug administration
- Donation of blood ≥ 500 mL within 2 months before study drug administration
- History or positive laboratory evidence of Human immunodeficiency virus (HIV), Hepatitis B antigen and antibody, or Hepatitis C, or history of Tuberculosis (TB) infection, or a positive result for Quantiferon Gold test
- Prolonged average of the corrected QTc by Fridericia's correction factor (QTcF) interval on screening electrocardiogram (ECG) triplicate (≥ 450 ms for males and ≥ 470 ms for females)
- Abnormal laboratory values that are considered clinically significant by the Investigator
- History of cancer
- History of eating disorders within the past 3 months
- History of a seizure disorder or clinically significant head injury
- Positive urine drug screen for drugs of abuse including alcohol
- Active infection within 90 days of check-in
- Medical condition, serious intercurrent illness, cardiovascular, pulmonary, neurologic, psychiatric, renal, hepatic or gastrointestinal disease, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize subject safety or interfere with the objectives of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Healthy volunteers will either receive AC430 or placebo.
|
ACTIVE_COMPARATOR: AC430
|
Healthy volunteers will either receive AC430 or placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.
Time Frame: 6 months
|
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the pharmacodynamic effects of single and multiple oral doses of AC430.
Time Frame: Measured at specific timepoints prior to and following dosing regimen.
|
|
Measured at specific timepoints prior to and following dosing regimen.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (ACTUAL)
June 1, 2011
Study Completion (ACTUAL)
June 1, 2011
Study Registration Dates
First Submitted
January 12, 2011
First Submitted That Met QC Criteria
January 31, 2011
First Posted (ESTIMATE)
February 2, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
November 1, 2015
Last Update Submitted That Met QC Criteria
October 29, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC430-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar